Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Enhanced Anti-glioblastoma Efficacy By PTX-loaded PEGylated Poly(ɛ-caprolactone) Nanoparticles: In Vitro And In Vivo Evaluation.
Hongliang Xin, Liangcen Chen, Jijin Gu, Xiaoqing Ren, Z. Wei, Jieqi Luo, Yanzuo Chen, Xinyi Jiang, X. Sha, X. Fang
Published 2010 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The aim of this work was to investigate the anti-tumor effect of paclitaxel (PTX)-loaded methoxy poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles (MPEG-NP/PTX) against glioblastoma multiforme (GBM). MPEG-NP/PTX was prepared by the emulsion and evaporation technique with particle size of 72.5±2.2nm and did not change remarkably during the period of 21-day storage at 4°C. The drug-loading coefficient and encapsulation ratio of optimized formulation were 8.2±0.6% and 90.4±2.3%, respectively. The in vitro release behavior exhibits a biphase release manner and was affected by PEG segment. In vitro cytotoxicity was assessed using C6 cell lines and was compared to Taxol and PTX-loaded poly(ɛ-caprolactone) conventional nanoparticles (NP/PTX). Cell viability assay against C6 cells exhibited higher or at least comparable cytotoxicity than that of Taxol and NP/PTX. More importantly, in vivo real-time fluorescence imaging analysis in intracranial C6 glioblastoma bearing mice showed that the methoxy poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles (MPEG-NP) displayed much stronger fluorescence signal and 3-fold larger Area-Under-Curve (AUC) than poly(ɛ-caprolactone) conventional nanoparticles (NP) in tumor-bearing brain. Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days). Therefore, MPEGylated poly(ɛ-caprolactone) nanoparticles significantly enhanced the anti-glioblastoma activity of PTX and might be considered a promising drug delivery system against advanced glioblastoma.
This paper references
Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.
Zhiqing Pang (2008)
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy.
Yuancai Dong (2007)
Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat
P. Calvo (2002)
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.
E. Allard (2009)
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.
Anja Zensi (2009)
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model.
A. Moore (2000)
A. Kanner (2007)
Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Yongzhong Wang (2007)
Effect of PEGconformation andparticle size on the cellular uptake efficiency of nanoparticles with the HepG 2 cells
S. C. ugminder (2002)
Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization.
Z. Wei (2009)
A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
T. Postma (2000)
Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.
Y. Hu (2007)
Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system.
A. Friese (2000)
Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles.
Yong Woo Cho (2004)
Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)/poly(epsilon-caprolactone) (PCL) amphiphilic block copolymeric nanospheres. II. Thermo-responsive drug release behaviors.
S. Kim (2000)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
B. Petri (2007)
Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery
P. Calvo (2004)
BIODEGRADABLE POLY (E-CAPROLACTONE) NANOPARTICLES FOR TUMOR-TARGETED DELIVERY OF TAMOXIFEN
J. S. Chawla (2002)
Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo.
Zhenshu Zhu (2010)
Cremophor EL, solvent for paclitaxel, and toxicity
J. Liebmann (1993)
High-grade glioma mouse models and their applicability for preclinical testing.
N. D. de Vries (2009)
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
A. Gulyaev (2004)
A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants
S. Chang (2001)
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs.
Yuancai Dong (2004)
Body distribution of polysorbate‐80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats
Alessandra Ambruosi (2005)
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
F. Danhier (2009)
Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect.
P. Stewart (1987)
Nanopar - ticle technology for drug delivery across the blood – brain
B. Y. Ong
Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
P. Grabb (1995)
Poly-ε-caprolactone and its copolymers
C. Pitt (1990)
What the cell "sees" in bionanoscience.
Dorota Walczyk (2010)
Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity
J. Olivier (2004)
Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations.
Ankita Desai (2008)
Poly(ethylene glycol)-block-poly(d,l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery
J. Shen (2011)
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats
Alessandra Ambruosi (2006)
PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics1
M. Peracchia (1997)
Biodegradable polymers as drug delivery systems
M. Chasin (1990)
Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with pluronic P105/poly(caprolactone) copolymers.
Yongzhong Wang (2008)
Pharmacological Effects of Formulation Vehicles
A. J. Tije (2003)
Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery.
Rutian Li (2009)
Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles
J. Kreuter (1997)
Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier
J. Kreuter (2002)
Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent
W. S. Enochs (1999)
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
S. C. Steiniger (2004)
Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance.
Wei Zhang (2010)
Incorporation and Release of Hydrophobic Probes in Biocompatible Polycaprolactone-block-poly(ethylene oxide) Micelles: Implications for Drug Delivery
P. Soo (2002)
Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123
Li-mei Han (2006)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2
A. Régina (2008)
Biodegradable poly ( - caprolactone ) nanoparticles for tumortargeted delivery of tamoxifen
Y. M. Lee (2000)
Paclitaxel concentrations in brain tumor tissue
J. W. Xie
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging
Hongtao Chen (2008)
The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles.
Z. Zhang (2006)
Polymers and nanoparticles: intelligent tools for intracellular targeting?
M. Breunig (2008)
Pharmacological effects of formulation vehicles : implication for canner chemotherapy
A. J. Ten tije
Biodegradable poly ( - caprolactone ) nanoparticles for tumortargeted delivery of tamoxifen
H. T. hen (2002)
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
J. Kreuter (2007)
Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles
R. Alyautdin (2004)
Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme.
Benjamin Y S Ong (2009)
The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines
J. Liebmann (2004)
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
L. Mu (2003)
Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles.
G. Gaucher (2009)
Hypersensitivity reactions from taxol.
R. Weiss (1990)
Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
C. Zhan (2010)
This paper is referenced by
The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells
Y. Xu (2016)
Preparation and anticancer activity evaluation of self-assembled paclitaxel conjugated MPEG-PCL micelles on 4T1 cells
Y. S. Lee (2019)
Liprosomes loading paclitaxel for brain-targeting delivery by intravenous administration: in vitro characterization and in vivo evaluation.
B. Tang (2014)
Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect
H. Rahman (2013)
Nanoparticles as Targeted Drug Delivery Agents: Synthesis, Mechanism and Applications
Nanomedicine and Brain Tumors Treatment
G. Caruso (2012)
Nanoparticles: Novel vehicles in treatment of Glioblastoma.
F. Pourgholi (2016)
Applications of Multifunctional Nanoparticles in Malignant Brain Tumours
C. Hadjipanayis (2013)
Fluorescent micelles based on star amphiphilic copolymer with a porphyrin core for bioimaging and drug delivery.
Luzhong Zhang (2012)
Influence of surface charge on the in vitro protein adsorption and cell cytotoxicity of paclitaxel loaded poly(ε-caprolactone) nanoparticles
S. Nandhakumar (2017)
Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells
J. Jiang (2017)
Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
M. Zhou (2017)
Nanoparticles potential: types, mechanisms of action, actual in vitro and animal studies, recent patents
G. Caruso (2015)
Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.
Sanjun Shi (2014)
Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy
B. Baumann (2013)
Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel.
J. Emami (2015)
A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy
Tingjie Yin (2015)
Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles as a Treatment for Glioblastoma
J. M. Castaneda-Gill (2016)
Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy
S. Wan (2018)
Magnetic brain targeting of naproxen-loaded polymeric micelles: pharmacokinetics and biodistribution study.
Z. Karami (2019)
An Overview of Paclitaxel Delivery Systems
A. Prabakaran (2020)
Diagnostic and therapeutic uses of nanomaterials in the brain.
E. Garbayo (2014)
PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studies
Y. Liu (2017)
Particles from preformed polymers as carriers for drug delivery
K. Miladi (2014)
Development of implantable hydroxypropyl-β-cyclodextrin coated polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors
Cem Varan (2014)
Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
Hongliang Xin (2011)
Long-Acting Paliperidone Parenteral Formulations Based on Polycaprolactone Nanoparticles; the Influence of Stabilizer and Chitosan on In Vitro Release, Protein Adsorption, and Cytotoxicity
M. Elmowafy (2020)
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo
X. Wu (2014)
Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment.
Xinyi Jiang (2014)
Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design
S. Adesina (2014)
PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.
Xinyi Jiang (2011)
iRGD‐paclitaxel conjugate nanoparticles for targeted paclitaxel delivery
H. Hu (2019)See more